検索結果

huhei Yoshida; hereinafter: Senju) is developing a compound (development code: SJP-0132) discovered by Mochida Pharmaceutical Co., Ltd. (Head office: Tokyo, Japan; President: Mr. Naoyuki Mochida; here...

Our Initiatives for Society/Environment | About Senju | SENJU Pharmaceutical

onsumers and patients. The role of the Center is to contribute to the proper use of pharmaceuticals by promptly and conscientiously providing customers with useful information about all our company�...

shida; hereinafter: Senju) is developing a TRPV1 antagonist (development code: SJP-0132) discovered by Mochida Pharmaceutical Co., Ltd. (Head office: Tokyo, Japan; President: Mr. Naoyuki Mochida; here...

NewMytear CL Cool Hi-s | OTC Products, etc. | Products | SENJU Pharmaceutical

STICS This medicine can be used while wearing all types of contact lenses (hard, soft). Can be used by persons who do not wear contact lenses. An eye drop containing potassium chloride and sodium chlo...

ical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr. Shuhei Yoshida; hereinafter “Senju”) hereby announces that the orphan drug designation to the in-house developed compound having the developm...